




Instance: composition-en-aac724bbfae048108e8444486a06d7e6
InstanceOf: CompositionUvEpi
Title: "Composition for aquipta Package Leaflet"
Description:  "Composition for aquipta Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpaac724bbfae048108e8444486a06d7e6)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - aquipta"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What AQUIPTA is and what it is used for</li>
<li>What you need to know before you take AQUIPTA</li>
<li>How to take AQUIPTA</li>
<li>Possible side effects</li>
<li>How to store AQUIPTA</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What aquipta is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What aquipta is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AQUIPTA contains the active substance atogepant. AQUIPTA is used to prevent migraine in adult 
patients who have at least 4 migraine days per month.
AQUIPTA is thought to block the activity of the calcitonin/calcitonin gene related peptide (CGRP)-
receptor family, which have been linked to migraine.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take aquipta"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take aquipta"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take AQUIPTA</p>
<p>if you are allergic to atogepant or any of the other ingredients of this medicine (listed in 
section 6).
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before taking AQUIPTA if you have severe liver problems.
Children and adolescents 
Do not give this medicine to children or adolescents under 18 years old because the use of AQUIPTA 
has not been studied in this age group.
Other medicines and AQUIPTA
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. Some medicines may increase the risk of getting side effects (see section 4).
The following is a list of examples of medicines that may require your doctor to lower the dose of
AQUIPTA:</p>
<p>ketoconazole, itraconazole, clarithromycin, rifampicin (medicines used to treat fungal or 
bacterial infections)</p>
<p>ritonavir (medicine used to treat HIV)</p>
<p>ciclosporin (medicine that affects your immune system)
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before using this medicine.
If you are pregnant, you should not take AQUIPTA. If you are a woman who could become pregnant,
you should use adequate contraception during treatment with AQUIPTA.
If you are breast-feeding or are planning to breast-feed, you should not take AQUIPTA. You and your 
doctor should decide if you will breast-feed or take AQUIPTA.
Driving and using machines
AQUIPTA may make you feel sleepy. Do not drive or use machines if you are affected.
AQUIPTA contains sodium
AQUIPTA 10 mg tablets
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free .
AQUIPTA 60 mg tablets 
This medicine contains 31.5 mg sodium (main component of cooking/table salt) in each tablet. This is 
equivalent to 1.6% of the recommended maximum daily dietary intake of sodium for an adult.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take aquipta"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take aquipta"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.
How much to take
The recommended dose is 60 mg atogepant once a day. Your doctor may tell you to take a lower dose 
if:</p>
<p>you are taking other medicines (listed in section 2)</p>
<p>you have severe kidney problems or you are undergoing dialysis.
How to take
AQUIPTA is for oral use. Do not split, crush, chew or break the tablet before swallowing. The tablets
may be taken with or without food.
If you take more AQUIPTA than you should
If you have taken more tablets than you should, tell your doctor. You may get some of the side effects 
listed in section 4. If you forget to take AQUIPTA</p>
<p>If you miss a dose, take it as soon as you remember.</p>
<p>If you forget your dose for an entire day, just skip the missed dose and take a single dose as 
usual the following day.</p>
<p>Do not take a double dose to make up for a forgotten dose.
If you stop taking AQUIPTA
Do not stop taking AQUIPTA without talking to your doctor first. Your symptoms may return if you 
stop the treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor if you notice any of the following side effects:
Common (may affect up to 1 in 10 people):</p>
<p>nausea (feeling sick in your stomach)</p>
<p>constipation</p>
<p>fatigue (tiredness)</p>
<p>somnolence (sleepiness)</p>
<p>decreased appetite</p>
<p>weight loss
Uncommon (may affect up to 1 in 100 people)</p>
<p>increased levels of liver enzymes
Not known (cannot be estimated from the available data)</p>
<p>allergic reactions (such as rash, itching, hives, swelling of the face)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listing in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store aquipta"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store aquipta"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What AQUIPTA contains
AQUIPTA 10 mg tablets</p>
<p>The active substance is atogepant. Each tablet contains 10 mg of atogepant.</p>
<p>The other ingredients are: Polyvinylpyrrolidone/Vinyl acetate copolymer, vitamin E 
polyethylene glycol succinate, mannitol, microcrystalline cellulose, sodium chloride, 
croscarmellose sodium, colloidal silicon dioxide and sodium stearyl fumarate (see section 2).
AQUIPTA 60 mg tablets</p>
<p>The active substance is atogepant. Each tablet contains 60 mg of atogepant.</p>
<p>The other ingredients are: Polyvinylpyrrolidone/Vinyl acetate copolymer, vitamin E 
polyethylene glycol succinate, mannitol, microcrystalline cellulose, sodium chloride, 
croscarmellose sodium, colloidal silicon dioxide and sodium stearyl fumarate (see section 2).
What AQUIPTA looks like and contents of the pack
AQUIPTA 10 mg tablets
AQUIPTA 10 mg tablet is a white to off-white, round biconvex tablet debossed with  A  and  10  on 
one side. It is available in packs containing 28 or 98 tablets.
AQUIPTA 60 mg tablets
AQUIPTA 60 mg tablet is a white to off-white, oval biconvex tablet debossed with  A60  on one side.
It is available in packs containing 28 or 98 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
AbbVie Deutschland GmbH &amp; Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
Manufacturer
AbbVie S.r.l
S.R. 148 Pontina Km 52 Snc
Campoverde di Aprilia, Latina 04Italy
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
AbbVie SA
T l/Tel: +32 10 477Lietuva
AbbVie UAB 
Tel: +370 5 205 3 </p>
<p>.:+359 2 90 30 Luxembourg/Luxemburg
AbbVie SA
Belgique/Belgien
T l/Tel: +32 10 477 esk  republika
AbbVie s.r.o. 
Tel: +420 233 098 Magyarorsz g
AbbVie Kft.
Tel.:+36 1 455 8Danmark
AbbVie A/S
Tlf: +45 72 30-20-Malta
Vivian Corporation Ltd. 
Tel: +356 27780Deutschland
AbbVie Deutschland GmbH &amp; Co. KG
Tel: 00800 222843 33 (geb hrenfrei)
Tel: +49 (0) 611 / 1720-0
Nederland
AbbVie B.V.
Tel:  +31 (0)88 322 2Eesti
AbbVie O 
Tel: +372 623 1Norge
AbbVie AS
Tlf: +47 67 81 80<br />
AbbVie    . .
 : +30 214 4165  sterreich
AbbVie GmbH 
Tel: +43 1 20589-0
Espa a
AbbVie Spain, S.L.U.
Tel:  +34 91 384 09 Polska
AbbVie Sp. z o.o.
Tel.: +48 22 372 78 France
AbbVie
T l: +33 (0) 1 45 60 13 Portugal
AbbVie, Lda. 
Tel: +351 (0)21 1908Hrvatska 
AbbVie d.o.o.
Tel + 385 (0)1 5625 Rom nia
AbbVie S.R.L.
Tel: +40 21 529 30 Ireland
AbbVie Limited 
Tel: +353 (0)1 4287Slovenija
AbbVie Biofarmacevtska dru ba d.o.o.
Tel: +386 (1)32 08  sland
Vistor hf.
S mi: +354 535 7Slovensk  republika
AbbVie s.r.o.
Tel: +421 2 5050 0Italia
AbbVie S.r.l. 
Tel: +39 06 928Suomi/Finland
AbbVie Oy 
Puh/Tel:  +358 (0)10 2411<br />
Lifepharma (Z.A.M.) Ltd
 .: +357 22 34 74 Sverige
AbbVie AB
Tel:  +46 (0)8 684 44 Latvija
AbbVie SIA 
Tel: +371 67605United Kingdom (Northern Ireland)
AbbVie Deutschland GmbH &amp; Co. KG
Tel: +44 (0)1628 561This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu/.
To listen to or request a copy of this leaflet in <em>Braille</em>, <em>large print</em> or <em>audio</em>, please contact 
the local representative of the Marketing Authorisation Holder.</p>         </div>"""      



Instance: composition-da-aac724bbfae048108e8444486a06d7e6
InstanceOf: CompositionUvEpi
Title: "Composition for aquipta Package Leaflet"
Description:  "Composition for aquipta Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpaac724bbfae048108e8444486a06d7e6)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - aquipta"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage AQUIPTA
3. Sådan skal du tage AQUIPTA
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What aquipta is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What aquipta is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AQUIPTA indeholder det aktive stof atogepant. AQUIPTA bruges til at forebygge migræne hos 
voksne patienter, der har mindst 4 migrænedage pr. måned.
AQUIPTA menes at virke ved at blokere aktiviteten af det  calcitonin /calcitonin-gen relaterede peptid 
fra (CGRP)-receptor familien, som er blevet forbundet med migræne. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take aquipta"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take aquipta"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke AQUIPTA

hvis du er allergisk over for atogepant eller et af de øvrige indholdsstoffer i AQUIPTA (angivet 
i punkt 6).
Advarsler og forsigtighedsregler
Tal med lægen, apotekspersonalet eller sygeplejersken, før du tager AQUIPTA, hvis du har alvorlige
leverproblemer.
Børn og unge 
Giv ikke dette lægemiddel til børn eller unge under 18 år, da brugen af AQUIPTA ikke er undersøgt 
hos denne aldersgruppe.
Brug af andre lægemidler sammen med AQUIPTA
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget 
andre lægemidler eller planlægger at tage andre lægemidler. Nogle lægemidler kan øge risikoen for at 
få bivirkninger (se punkt 4).
29
Følgende er en liste med eksempler på lægemidler, der kan kræve, at din læge mindsker dosis af 
AQUIPTA:

ketoconazol, itraconazol, clarithromycin, rifampicin (lægemidler til behandling af svampe- eller 
bakterieinfektioner

ritonavir (lægemiddel til behandling af hiv)

ciclosporin (lægemiddel, der påvirker dit immunsystem)
Graviditet, amning og frugtbarhed
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du bruger dette lægemiddel.
Hvis du er gravid, må du ikke tage AQUIPTA. Hvis du er en kvinde, der kan blive gravid, skal du 
bruge sikker prævention under behandlingen med AQUIPTA. 
Hvis du ammer eller planlægger at amme, må du ikke tage AQUIPTA. Du og din læge skal beslutte, 
om du skal amme eller tage AQUIPTA.
Trafik- og arbejdssikkerhed
AQUIPTA kan gøre dig søvnig. Du må ikke føre motorkøretøj eller betjene maskiner, hvis du er 
påvirket.
AQUIPTA indeholder natrium
AQUIPTA 10 mg tabletter
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit.
AQUIPTA 60 mg tabletter 
Dette lægemiddel indeholder 31,5 mg natrium (hovedkomponent af madlavnings-/bordsalt) pr. tablet. 
Dette svarer til 1,6 % af den anbefalede maksimale daglige indtagelse af natrium for en voksen.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take aquipta"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take aquipta"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet.
Så meget skal der tages
Den anbefalede dosis er 60 mg atogepant én gang dagligt. Din læge kan muligvis fortælle dig, at du 
skal tage en lavere dosis, hvis:

du tager andre lægemidler (angivet i punkt 2)

du har alvorlige nyreproblemer, eller du modtager dialyse.
Sådan tages lægemidlet
AQUIPTA er til oral anvendelse. Tabletten må ikke deles, knuses, tygges eller knækkes, før den 
sluges. Tabletterne kan tages sammen med eller uden mad.
Hvis du har taget for meget AQUIPTA
Hvis du har taget flere tabletter, end du bør, skal du fortælle det til lægen. Du kan få nogle af 
bivirkningerne anført i punkt 4. Hvis du har glemt at tage AQUIPTA

Hvis du har glemt en dosis, skal du tage den, så snart du kommer i tanke om det.

Hvis du har glemt din dosis en hel dag, skal du bare springe den glemte dosis over og tage en 
enkelt dosis som sædvanligt den følgende dag.

Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis.
30
Hvis du holder op med at tage AQUIPTA
Du må ikke holde op med at tage AQUIPTA uden først at tale med din læge. Dine symptomer kan 
vende tilbage, hvis du stopper behandlingen.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Fortæl det til lægen, hvis du bemærker nogen af de følgende bivirkninger:
Almindelig (kan forekomme hos op til 1 ud af 10 personer):

kvalme

forstoppelse

træthed 

søvnighed (somnolens)

nedsat appetit

vægttab
Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer)

forhøjede leverenzymtal
Ikke kendt (kan ikke estimeres ud fra forhåndenværende data)

allergiske reaktioner (som for eksempel udslæt, kløe, nældefeber, hævelse i ansigtet)
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store aquipta"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store aquipta"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisteren efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned.
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AQUIPTA indeholder
AQUIPTA 10 mg tabletter

Aktivt stof: atogepant. Hver tablet indeholder 10 mg atogepant.
31

Øvrige indholdsstoffer: Polyvinylpyrrolidon/vinylacetatcopolymer, E-vitamin 
polyethylenglycolsuccinat, mannitol, mikrokrystallinsk cellulose, natriumchlorid, 
croscarmellosenatrium, kolloid siliciumdioxid og natriumstearylfumarat (se punkt 2).
AQUIPTA 60 mg tabletter

Aktivt stof: atogepant. Hver tablet indeholder 60 mg atogepant.

Øvrige indholdsstoffer: Polyvinylpyrrolidon/vinylacetatcopolymer, E-vitamin 
polyethylenglycolsuccinat, mannitol, mikrokrystallinsk cellulose, natriumchlorid, 
croscarmellosenatrium, kolloid siliciumdioxid og natriumstearylfumarat (se punkt 2).
Udseende og pakningsstørrelser
AQUIPTA 10 mg tabletter
AQUIPTA 10 mg tablet er en hvid til off-white, rund bikonveks tablet præget med "A" og "10" på den 
ene side. Den fås i pakninger indeholdende 28 eller 98 tabletter.
AQUIPTA 60 mg tabletter
AQUIPTA 60 mg tablet er en hvid til off-white, oval bikonveks tablet præget med  "A60" på den ene 
side. Den fås i pakninger indeholdende 28 eller 98 tabletter. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen
AbbVie Deutschland GmbH &amp; Co. KG
Knollstrasse
67061 Ludwigshafen
Tyskland
Fremstiller
AbbVie S.r.l
S.R. 148 Pontina Km 52 Snc
Campoverde di Aprilia, Latina 04011
Italien
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
AbbVie SA
Tél/Tel: +32 10 477811
Lietuva
AbbVie UAB
Tel: +370 5 205 3023
България
АбВи ЕООД
Тел.: +359 2 90 30 430
Luxembourg/Luxemburg
AbbVie SA
Belgique/Belgien
Tél/Tel: +32 10 477811
Česká republika
AbbVie s.r.o.
Tel: +420 233 098 111
Magyarország
AbbVie Kft.
Tel.: +36 1 455 8600
Danmark
AbbVie A/S
Tlf: +45 72 30-20-28
Malta
Vivian Corporation Ltd.
Tel: +356 27780331
32
Deutschland
AbbVie Deutschland GmbH &amp; Co. KG
Tel: 00800 222843 33 (gebührenfrei)
Tel: +49 (0) 611 / 1720-0
Nederland
AbbVie B.V.
Tel: +31 (0)88 322 2843
Eesti
AbbVie OÜ
Tel: +372 623 1011
Norge
AbbVie AS
Tlf: +47 67 81 80 00
Ελλάδα
AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.
Τηλ: +30 214 4165 555
Österreich
AbbVie GmbH
Tel: +43 1 20589-0
España
AbbVie Spain, S.L.U.
Tel: +34 91 384 09 10
Polska
AbbVie Sp. z o.o.
Tel.: +48 22 372 78 00
France
AbbVie
Tél: +33 (0) 1 45 60 13 00
Portugal
AbbVie, Lda.
Tel: +351 (0)21 1908400
Hrvatska 
AbbVie d.o.o.
Tel + 385 (0)1 5625 501
România
AbbVie S.R.L.
Tel: +40 21 529 30 35
Ireland
AbbVie Limited
Tel: +353 (0)1 4287900
Slovenija
AbbVie Biofarmacevtska družba d.o.o.
Tel: +386 (1)32 08 060
Ísland
Vistor hf.
Sími: +354 535 7000
Slovenská republika
AbbVie s.r.o.
Tel: +421 2 5050 0777
Italia
AbbVie S.r.l.
Tel: +39 06 928921
Suomi/Finland
AbbVie Oy
Puh/Tel: +358 (0)10 2411 200
Κύπρος
Lifepharma (Z.A.M.) Ltd
Τηλ.: +357 22 34 74 40
Sverige
AbbVie AB
Tel: +46 (0)8 684 44 600
Latvija
AbbVie SIA
Tel: +371 67605000
United Kingdom (Northern Ireland)
AbbVie Deutschland GmbH &amp; Co. KG
Tel: +44 (0)1628 561090
Denne indlægsseddel blev senest ændret
Andre informationskilder
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/.
Hvis du ønsker at rekvirere denne indlægsseddel i <em>brailleskrift</em> eller &lt; magnaprint&gt; eller som 
<em>lydfil</em>, kan du kontakte den lokale repræsentant for indehaveren af markedsføringstilladelsen.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-aac724bbfae048108e8444486a06d7e6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for aquipta Package Leaflet for language en"
Description: "ePI document Bundle for aquipta Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-aac724bbfae048108e8444486a06d7e6"
* entry[0].resource = composition-en-aac724bbfae048108e8444486a06d7e6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpaac724bbfae048108e8444486a06d7e6"
* entry[=].resource = mpaac724bbfae048108e8444486a06d7e6
                            
                    
Instance: bundlepackageleaflet-da-aac724bbfae048108e8444486a06d7e6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for aquipta Package Leaflet for language da"
Description: "ePI document Bundle for aquipta Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-aac724bbfae048108e8444486a06d7e6"
* entry[0].resource = composition-da-aac724bbfae048108e8444486a06d7e6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpaac724bbfae048108e8444486a06d7e6"
* entry[=].resource = mpaac724bbfae048108e8444486a06d7e6
                            
                    



Instance: mpaac724bbfae048108e8444486a06d7e6
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product AQUIPTA 10 mg tablets"
Description: "AQUIPTA 10 mg tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/23/1750/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "AQUIPTA 10 mg tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: aac724bbfae048108e8444486a06d7e6ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "aquipta"

* status = #current
* mode = #working

* title = "List of all ePIs associated with aquipta"

* subject = Reference(mpaac724bbfae048108e8444486a06d7e6)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#aquipta "aquipta"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-aac724bbfae048108e8444486a06d7e6) // aquipta en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-aac724bbfae048108e8444486a06d7e6) // aquipta da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-aac724bbfae048108e8444486a06d7e6
InstanceOf: List

* insert aac724bbfae048108e8444486a06d7e6ListRuleset
    